Ferring Makes Foray Into Gene Therapy With FKD Pact
The Swiss company's CMO Klaus Dugi tells Scrip that getting the rights to a late-stage bladder cancer gene therapy from Finland's FKD highlights the transformation that Ferring is undergoing.
You may also be interested in...
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.
The latest drug development news and highlights from our US FDA Performance Tracker.
Ferring announced this morning (Oct. 31) that Michel Pettigrew is retiring as president of the executive board and will be succeeded by CSO Per Falk. The two spoke to Scrip recently and outlined the Swiss-based firm's future strategy.